Olodaterol/tiotropium cost  effective for COPD in UK

Source: PharmacoEconomics and Outcomes News - Category: Drugs & Pharmacology Source Type: news

Related Links:

Conclusion: The varied spectra of COVID-19 mostly affects young adult age group (third to fifth decades of life). Interestingly, early age group was also affected in significant proportion when compared with similar data from other countries. It was observed that male population seemed to be was more prone to getting infected. Majority of COVID-19 positive patients (nearly three-fourth) were asymptomatic (mostly in young age range) at the time of diagnosis, which poses a major challenge for health care workers. Fever, cough, sore throat and shortness of breath were major symptoms that could be detected in such COVID-19 pat...
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
Conclusion: Clinical investigations in initial Covid-19 patients in the Indian subcontinent reveal lymphopenia as predominant finding in hemogram. Patients with older age and associated comorbid conditions (COPD and diabetes) seem to have greater risk for lung injury thereby requiring oxygen support during the course of disease and these patients also had greater derangement in their biochemical profile. PMID: 32610859 [PubMed - in process]
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
AireHealth, a medtech company based in Orlando, Florida, currently offers a portable nebulizer and companion app for respiratory patients aged two and over. The small nebulizer can be charged using a micro USB charger and then placed in a bag or pock...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Informatics Medicine Telemedicine AireHealth Source Type: blogs
In conclusion, cigarette smoking was proved to be the most significant risk factor for development of pulmonary tuberculosis and its recurrence. PMID: 32595242 [PubMed - in process]
Source: Acta Clinica Croatica - Category: General Medicine Tags: Acta Clin Croat Source Type: research
Publication date: September 2020Source: Biomedicine &Pharmacotherapy, Volume 129Author(s): Jingjing Mei, Yuan Zhang, Shuangshuang Lu, Jing Wang
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Authors: Calzetta L, Matera MG, Rogliani P, Cazzola M Abstract INTRODUCTION: Triple therapy in COPD is becoming increasingly important with the cumulative documentation of its ability to reduce the risk of AECOPD. However, it must be established which patients benefit most from it compared to other treatments. AREAS COVERED: We critically review the literature to determine, if possible, the real role of triple therapy in the treatment of COPD. We have identified studies from several databases and selected the information thought to be more significant. EXPERT OPINION: It is still unclear whether and when ad...
Source: Expert Review of Clinical Pharmacology - Category: Drugs & Pharmacology Tags: Expert Rev Clin Pharmacol Source Type: research
CONCLUSIONS: Coal mine fire smoke created a substantial health burden. People with respiratory diseases should receive targeted messages, follow self-management plans and take preventive medication during future coal mine fires. PMID: 32278916 [PubMed - indexed for MEDLINE]
Source: Chemosphere - Category: Chemistry Authors: Tags: Chemosphere Source Type: research
This report describes a new study that shows annual medical expenditures in the public administration industry had the highest medical expenditure per person for treatment of both diseases.
Source: CDC Morbidity and Mortality Weekly Report - Category: American Health Tags: Asthma Chronic Obstructive Pulmonary Disease (COPD) Health Care Expenditures MMWR Morbidity & Mortality Weekly Report Workplace Safety Source Type: news
Condition:   Chronic Obstructive Pulmonary Disease Interventions:   Drug: Dupilumab SAR231893;   Drug: Inhaled Corticosteroid;   Drug: Inhaled Long-Acting Beta Agonist;   Drug: Inhaled Long-Acting Muscarinic Antagonist;   Drug: Placebo Sponsors:   Sanofi;   Regeneron Pharmaceuticals Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Asthma;   COPD Intervention:   Sponsor:   Ryazan State Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Obstructive Pulmonary | Drugs & Pharmacology | Spiriva | Tiotropium